Search by Drug Name or NDC
NDC 00054-0399-25 Bexarotene 75 mg/1 Details
Bexarotene 75 mg/1
Bexarotene is a ORAL CAPSULE, LIQUID FILLED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Hikma Pharmaceuticals USA Inc.. The primary component is BEXAROTENE.
MedlinePlus Drug Summary
Bexarotene is used to treat cutaneous T-cell lymphoma (CTCL, a type of skin cancer) in people whose disease could not be treated successfully with at least one other medication. Bexarotene is in a class of medications called retinoids. It works by stopping the growth of cancer cells.
Related Packages: 00054-0399-25Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Bexarotene
Product Information
| NDC | 00054-0399 |
|---|---|
| Product ID | 0054-0399_84e77a4e-27da-404f-8386-b9255d465b1d |
| Associated GPIs | 21708220000120 |
| GCN Sequence Number | 044269 |
| GCN Sequence Number Description | bexarotene CAPSULE 75 MG ORAL |
| HIC3 | V1N |
| HIC3 Description | ANP - SELECTIVE RETINOID X RECEPTOR AGONISTS (RXR) |
| GCN | 92373 |
| HICL Sequence Number | 020832 |
| HICL Sequence Number Description | BEXAROTENE |
| Brand/Generic | Generic |
| Proprietary Name | Bexarotene |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | bexarotene |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE, LIQUID FILLED |
| Route | ORAL |
| Active Ingredient Strength | 75 |
| Active Ingredient Units | mg/1 |
| Substance Name | BEXAROTENE |
| Labeler Name | Hikma Pharmaceuticals USA Inc. |
| Pharmaceutical Class | Retinoid [EPC], Retinoids [CS] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA203663 |
| Listing Certified Through | 2025-12-31 |
Package
NDC 00054-0399-25 (00054039925)
| NDC Package Code | 0054-0399-25 |
|---|---|
| Billing NDC | 00054039925 |
| Package | 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (0054-0399-25) |
| Marketing Start Date | 2020-11-11 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |